Wegovy vs Ozempic: Same Drug, Different Doses (UK 2026)

Understanding Semaglutide: The Science Behind Both Brands

Wegovy and Ozempic represent two faces of the same pharmaceutical coin. Both medications contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. The fundamental molecule remains identical—what differs is the approved indication, dosing protocol, and regulatory positioning in the UK healthcare system.

Semaglutide works by mimicking the incretin hormone GLP-1, which naturally regulates blood sugar levels and gastric emptying. The STEP clinical trial programme, comprising STEP-1 through STEP-8, demonstrated semaglutide's efficacy for weight management, whilst the SUSTAIN trials established its role in type 2 diabetes management.

Key Differences: Approved Uses and Indications

Ozempic: The Diabetes Specialist

Ozempic received its UK marketing authorisation specifically for type 2 diabetes management. The medication is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Research from the SUSTAIN trials demonstrated significant HbA1c reductions, with SUSTAIN-6 showing cardiovascular benefits in high-risk patients.

The NHS typically prescribes Ozempic when metformin alone proves insufficient, or when patients cannot tolerate other diabetes medications. NICE guidelines support its use within established diabetes care pathways, making it readily accessible through standard GP prescriptions.

Wegovy: The Weight Management Solution

Wegovy holds a distinct licence for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight individuals (BMI ≥27 kg/m²) with at least one weight-related comorbidity. The STEP-1 trial demonstrated that participants achieved an average weight reduction of 14.9% over 68 weeks, significantly higher than placebo groups.

Unlike Ozempic's diabetes indication, Wegovy's approval focuses exclusively on weight management as an adjunct to reduced-calorie diet and increased physical activity.

Dosing Protocols: Where the Differences Matter

Aspect	Ozempic	Wegovy
Maximum Dose	2.0mg weekly	2.4mg weekly
Starting Dose	0.25mg weekly	0.25mg weekly
Escalation	0.25mg → 0.5mg → 1.0mg → 2.0mg	0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg
Approved Use	Type 2 diabetes	Weight management
NHS Availability	Standard diabetes prescription	Specialist weight management services
Private Cost (UK)	£73-150/month	£200-250/month
Pen Colours	Blue and red	Blue

Ozempic Dosing Strategy

Ozempic's dosing begins at 0.25mg weekly for four weeks, primarily to minimise gastrointestinal side effects. The dose typically increases to 0.5mg weekly, with further escalation to 1.0mg and potentially 2.0mg based on glycaemic control and tolerability.

Wegovy's Higher Dose Protocol

Wegovy follows a more extended escalation schedule, ultimately reaching 2.4mg weekly. This higher dose, validated in the STEP trials, proved necessary to achieve optimal weight loss outcomes. The additional 0.4mg weekly dose represents a 20% increase over Ozempic's maximum, contributing to enhanced weight reduction effects.

NHS Availability and NICE Criteria

Ozempic on the NHS

Ozempic enjoys straightforward NHS availability for eligible type 2 diabetes patients. GPs can prescribe it following standard diabetes care protocols, typically when:

• HbA1c remains above target despite metformin therapy
• Other diabetes medications prove unsuitable or ineffective
• Cardiovascular risk factors warrant GLP-1 receptor agonist therapy

The medication forms part of established diabetes treatment pathways, ensuring consistent access across England, Scotland, Wales, and Northern Ireland.

Wegovy's Restricted NHS Access

Wegovy's NHS availability operates under strict NICE criteria, limiting access to specialist weight management services. Patients must meet specific requirements:

• BMI ≥35 kg/m² with at least one obesity-related comorbidity
• Previous unsuccessful weight loss attempts through lifestyle interventions
• Referral from primary care to specialist services
• Commitment to ongoing lifestyle support programmes

This restricted access creates significant barriers for many patients seeking weight management support, often driving them towards private prescription routes.

Private Prescription Costs in the UK

Private prescription costs vary considerably between the two medications. Ozempic typically costs £73-150 per month through private clinics, whilst Wegovy commands £200-250 monthly. These price differences reflect market positioning, with Wegovy's obesity indication commanding premium pricing.

Many patients explore cost calculator tools to compare long-term financial commitments across different treatment options.

Off-Label Use: The Grey Areas

Can Ozempic Be Used for Weight Loss?

Some UK GPs prescribe Ozempic off-label for weight loss, particularly for patients who don't meet Wegovy's NHS criteria but demonstrate medical need. This practice remains controversial, as it uses a diabetes medication outside its licensed indication.

The identical active ingredient means Ozempic can produce weight loss effects, though the lower maximum dose (2.0mg vs 2.4mg) may reduce efficacy compared to Wegovy. However, off-label prescribing requires careful consideration of regulatory and insurance implications.

Can Wegovy Treat Diabetes?

Wegovy lacks approval for diabetes management, despite containing the same active molecule. Prescribing Wegovy for diabetes would constitute off-label use, creating regulatory complications and potential insurance issues.

Patients with both diabetes and obesity often benefit more from Ozempic, which addresses both conditions whilst remaining within licensed indications.

Side Effects: Nearly Identical Profiles

Both medications share virtually identical side effect profiles, reflecting their common active ingredient. The most frequently reported adverse effects include:

• Nausea (20-40% of patients)
• Vomiting (9-24% of patients)
• Diarrhoea (8-19% of patients)
• Constipation (6-24% of patients)
• Abdominal pain (6-20% of patients)

Gastrointestinal effects typically diminish over 4-8 weeks as patients adapt to treatment. The gradual dose escalation protocol helps minimise initial side effects across both formulations.

More serious but rare side effects include pancreatitis, gallbladder disorders, and potential thyroid C-cell tumours (based on rodent studies). Both medications carry identical contraindications and precautions.

Choosing Between Ozempic and Wegovy

The choice between these medications rarely involves patient preference—regulatory approvals and NHS criteria typically determine accessibility. Key decision factors include:

For Type 2 Diabetes Patients

• Ozempic remains the appropriate choice
• Standard NHS prescription availability
• Lower private prescription costs
• Established diabetes care pathways

For Weight Management Patients

• Wegovy provides optimal dosing for obesity treatment
• Higher maximum dose (2.4mg) for enhanced efficacy
• Requires specialist referral for NHS access
• Higher private prescription costs

For Dual Indication Patients

Patients with both diabetes and obesity face complex decisions. Many clinicians favour Ozempic for its dual benefits whilst remaining within licensed diabetes indications. Others may pursue Wegovy through specialist weight management services, particularly if diabetes remains well-controlled through other medications.

The Mounjaro Alternative

Some patients explore Mounjaro (tirzepatide) as an alternative, offering dual GIP/GLP-1 receptor agonism. The SURMOUNT trials demonstrated superior weight loss compared to semaglutide-based medications, though availability and costs differ significantly. Understanding semaglutide vs tirzepatide comparisons helps inform treatment decisions.

Storage and Handling Considerations

Both medications require identical storage protocols, maintaining temperatures between 2-8°C before first use. Once opened, pens remain stable for up to 56 days at room temperature. Proper peptide storage ensures medication efficacy and patient safety.

Future Considerations and Market Developments

The UK semaglutide market continues evolving, with potential biosimilar entries and expanded NHS access criteria. Patients should stay informed about changing availability and consider joining weight management protocols that support long-term success regardless of medication choice.

FAQ

What's the main difference between Wegovy and Ozempic?

Wegovy and Ozempic contain the same active ingredient (semaglutide) but differ in approved uses and maximum doses. Ozempic is licensed for type 2 diabetes with a maximum dose of 2mg weekly, whilst Wegovy is approved for weight management with a higher 2.4mg weekly dose.

Can I get Wegovy on the NHS?

Wegovy is available on the NHS but only through specialist weight management services under strict NICE criteria. You need a BMI ≥35 kg/m² with obesity-related comorbidities and must have tried other weight loss methods first. Most patients require private prescriptions.

Is Ozempic cheaper than Wegovy in the UK?

Yes, Ozempic typically costs £73-150 per month privately, whilst Wegovy costs £200-250 monthly. The price difference reflects different market positioning and regulatory approvals, though both medications contain identical active ingredients.

Can my GP prescribe Ozempic for weight loss?

Some GPs may prescribe Ozempic off-label for weight loss, though this uses a diabetes medication outside its licensed indication. This practice varies by clinic and requires careful consideration of regulatory implications. Wegovy remains the properly approved weight loss option.

Do Wegovy and Ozempic have the same side effects?

Yes, both medications share virtually identical side effect profiles since they contain the same active ingredient. Common effects include nausea, vomiting, diarrhoea, and constipation, typically diminishing over 4-8 weeks as your body adapts.

Which is more effective for weight loss: Ozempic 2mg or Wegovy 2.4mg?

Wegovy's higher 2.4mg dose generally provides superior weight loss results compared to Ozempic's 2mg maximum. The STEP trials demonstrated that this 20% dose increase contributes to enhanced weight reduction, making Wegovy the optimal choice for obesity treatment.

Can I switch from Ozempic to Wegovy?

Switching between these medications requires medical supervision, as they serve different approved purposes. If you're using Ozempic for diabetes, switching to Wegovy might affect blood sugar control. Always consult your prescribing clinician before making changes.

How long does it take to see results with either medication?

Weight loss typically begins within 4-8 weeks, with significant results evident by 12-16 weeks. For diabetes management with Ozempic, blood sugar improvements often occur within 2-4 weeks. Both medications require consistent use and lifestyle modifications for optimal results.